Seres Therapeutics, Inc. - 8-K Filing
Seres Therapeutics announced positive early clinical data for SER-155 in treating immune checkpoint inhibitor-related enterocolitis (irEC), with 80% achieving immunosuppressive-free response at Day 15. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $MCRB